CN103127077A - Application of Aphanamixoid A to dental ulcer treatment or prevention medicine - Google Patents
Application of Aphanamixoid A to dental ulcer treatment or prevention medicine Download PDFInfo
- Publication number
- CN103127077A CN103127077A CN 201210413017 CN201210413017A CN103127077A CN 103127077 A CN103127077 A CN 103127077A CN 201210413017 CN201210413017 CN 201210413017 CN 201210413017 A CN201210413017 A CN 201210413017A CN 103127077 A CN103127077 A CN 103127077A
- Authority
- CN
- China
- Prior art keywords
- aphanamixoid
- application
- ulcer
- treatment
- dental ulcer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The invention relates to application of Aphanamixoid A to preparation of dental ulcer treatment or prevention medicine. The application of the Aphanamixoid A to the preparation of the dental ulcer treatment or prevention medicine is made public for the first time. The skeleton type is fully novel, activity of the Aphanamixoid A in treating dental ulcer is surprisingly strong, the possibility that inspiration is obtained from other compounds does not exist, the Aphanamixoid A has prominent substantive features, and meanwhile, significant progress of the application of the Aphanamixoid A to treatment of the dental ulcer is obviously achieved.
Description
Technical field
The present invention relates to the application of Aphanamixoid A in preparation treatment or preventing canker sore medicine.
Background technology
Recurrent oral ulceration is modal disease in diseases of oral mucosa.The first place of prevalence office diseases of oral mucosa.Sircus(1975) investigation 1587 people, prevalence is 20%.This shows, oral ulcer patient is a very huge colony.The cause of disease of recurrent oral ulceration is complicated, and is still indefinite so far, may infect with viral infection, antibacterial and the factors such as the endocrine regulation of body, immune dysfunction relevant.
The primary treatment measure of oral ulcer comprises topical therapeutic and whole body therapeutic, and because the topical therapeutic toxic and side effects is lower, the people who has therefore obtained people can.Although the buccal tablets that use the part that occurs in recent years carries, easy to use, mouthfeel and compliance are better, and as lysozyme buccal tablet, watermelon crystal buccal tablet, cydiodine etc., these medicines emphasize particularly on different fields at aspects such as sterilization, antiinflammatory, pain relievings.
the compd A phanamixoid A that the present invention relates to is one and delivered (Cai in 2012, J. Y. et al., 2012. Aphanamixoid A, a Potent Defensive Limonoid, with a New Carbon Skeleton from Aphanamixis polystachya. Organic Letters 14 (10), 2524 – 2527.) New skeleton compound, this compound has brand-new framework types, present purposes only relates to insect antifeedant activity (Cai, J. Y. et al., 2012. Aphanamixoid A, a Potent Defensive Limonoid, with a New Carbon Skeleton from Aphanamixis polystachya. Organic Letters 14 (10), 2524 – 2527.), belong to open first for the purposes of the Aphanamixoid A that the present invention relates in preparation treatment stomatocace medicine, because framework types belongs to brand-new framework types, and its treatment oral ulcer is active unexpectedly strong, there is not the possibility that is provided any enlightenment by other compounds, possesses outstanding substantive distinguishing features, be used for the treatment of simultaneously oral ulcer and obviously have significant progress.
Summary of the invention
The invention provides the application of Aphanamixoid A in preparation treatment or preventing canker sore medicine.
Described compd A phanamixoid A structure is as shown in formula I:
The purposes in preparation treatment stomatocace medicine that the present invention relates to belongs to open first, because framework types belongs to brand-new framework types, and its treatment oral ulcer is active unexpectedly strong, there is not the possibility that is provided any enlightenment by other compounds, possess outstanding substantive distinguishing features, be used for the treatment of simultaneously oral ulcer and obviously have significant progress.
The specific embodiment
The preparation method of compd A phanamixoid A involved in the present invention is referring to document (Cai, J. Y. et al., 2012. Aphanamixoid A, a Potent Defensive Limonoid, with a New Carbon Skeleton from Aphanamixis polystachya. Organic Letters 14 (10), 2524 – 2527.).
The present invention is further detailed explanation by the following examples, but protection scope of the present invention is not subjected to any restriction of specific embodiment, but limited by claim.
Embodiment 1: the preparation of compd A phanamixoid A tablet involved in the present invention:
Get 20 and digest compound Aphanamixoid A, add conventional adjuvant 180 grams that prepare tablet, mixing, conventional tablet machine are made 1000.
Embodiment 2: the preparation of compd A phanamixoid A capsule involved in the present invention:
Get 20 and digest compound Aphanamixoid A, add the conventional adjuvant such as starch 180 grams that prepare capsule, mixing is encapsulatedly made 1000.
Further illustrate its pharmaceutically active below by pharmacodynamic experiment.
Test example 1 Aphanamixoid A anti-oral ulcer experimental study
1, test objective: whether make the oral ulcer model with phenol, give the Aphanamixoid A of the certain number of times of oral ulcer rat model every day, observing Aphanamixoid A has the effect that reduces ulcer.
2, tested medicine and reagent
Cydiodine (Beijing Sihuan Medicine Science and Technology Co., Ltd); Phenol
Animal: the Wistar rat, male, body weight 240 ~ 280
3, test method
Get 50 of rats, male, body weight 240 ~ 280g, 10% chloral hydrate anesthesia, dosage: 0.35ml/100g, after anesthesia, (internal diameter: 3mm) lower end is flat on the rats with left bicker approximately on the cheek film at 1mm place with the plastic dropper of 90% phenol cotton balls, calcination 30min namely sees the approximately white infringement of 3mm of this place.Grouping immediately after 24 hours, divides 5 groups, i.e. model group (4 times/days of adjuvants do not contain medicine) by 10 every group; Aphanamixoid A high dose group (4 times/days, 0.5mg/ time); Dosage in Aphanamixoid A (4 times/days, 0.1mg/ time); Aphanamixoid A low dose group (4 times/days, 0.02mg/ time); Positive controls: cydiodine group (4 times/days, 0.5mg/ time).Aphanamixoid A and cydiodine buccal tablet be pulverize before use, and administration is take flap coverage as degree.Successive administration 5 days, after reaching each administration before administration, observe ulcer area size (in the diameter of ulcer) and ulcer healing situation (being considered as healing without macroscopic ulcer) next day, and first administration to last administration is recorded as respectively 1,2,3,4,5,6,7 day.The ulcer area size is checked with t, ulcer healing rate X
2Check.
4, result of the test
Ulcer area is (table 1) relatively: Aphanamixoid A high dose group and model group relatively played off-test on the 3rd day from administration, and significant difference is relatively arranged corresponding every day; Cydiodine group and model group relatively played off-test on the 3rd day from administration, and significant difference is relatively arranged corresponding every day; In Aphanamixoid A, dosage group and model group relatively, played off-test on the 3rd day from administration, and significant difference is relatively arranged corresponding every day; Aphanamixoid A low dose group and model group relatively played off-test on the 5th day from administration, and significant difference is relatively arranged corresponding every day; In Aphanamixoid A, dosage group and cydiodine group relatively, played off-test on the 1st day from administration, and significant difference is relatively arranged corresponding every day.
The impact of table 1 on the rat ulcer area
Annotate: compare * p＜0.05, * p＜0.01 with model group.
Healing rate (table 2): adjuvant group and Aphanamixoid A low dose group played off-test on the 1st day from administration, and ulcer is healing not; And Aphanamixoid A high dose group just had ulcer healing from administration the 4th day, to off-test, reached 90%; The cydiodine group has ulcer healing from administration the 4th day, to off-test, reach 60%; In Aphanamixoid A, the dosage group from administration the 5th day, has ulcer healing, to off-test, reaches 40%.
The impact of table 2 on the rat ulcer healing time
Annotate: compare * p＜0.05, * p＜0.01 with model group.
5, conclusion
Aphanamixoid A has the effect of obvious promotion oral ulcer healing.
Claims (1)
1.Aphanamixoid the application of A in treatment or preventing canker sore medicine, described compd A phanamixoid A structure is as shown in formula I:
Formula I.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201210413017 CN103127077A (en) | 2012-10-25 | 2012-10-25 | Application of Aphanamixoid A to dental ulcer treatment or prevention medicine |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201210413017 CN103127077A (en) | 2012-10-25 | 2012-10-25 | Application of Aphanamixoid A to dental ulcer treatment or prevention medicine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN103127077A true CN103127077A (en) | 2013-06-05 |
Family
ID=48487952
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 201210413017 Withdrawn CN103127077A (en) | 2012-10-25 | 2012-10-25 | Application of Aphanamixoid A to dental ulcer treatment or prevention medicine |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103127077A (en) |
-
2012
- 2012-10-25 CN CN 201210413017 patent/CN103127077A/en not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103768308B (en) | A kind of pharmaceutical composition that is used for the treatment of the infection of the upper respiratory tract and preparation method thereof | |
| CN103585147B (en) | Application of Nitrosporeusines A in preparation of oral ulcer treatment or prevention medicines | |
| CN103462951B (en) | Application of scopariusins in preparation of medicine treating or preventing canker sore | |
| CN102988382B (en) | Application of Houttuynoid C for preparing medicine for treating or preventing dental ulcer | |
| CN107501435A (en) | The extracting method of pachymaran and its application | |
| CN103127077A (en) | Application of Aphanamixoid A to dental ulcer treatment or prevention medicine | |
| CN103263423A (en) | Application of myriberine A in preparation of medicaments for treating or preventing canker sores | |
| CN102872056B (en) | Application of Gypensapogenin A to preparing drugs for treating or preventing canker sores | |
| CN103599104B (en) | Application of Caesanines D in drug for treating or preventing dental ulcer | |
| CN103356653B (en) | The application of Chukrasone A in preparation treatment or preventing canker sore medicine | |
| CN103479624B (en) | Application of Racemosins A in preparation of oral ulcer treatment or prevention medicines | |
| CN106344555A (en) | Application of Fistulains B in drugs for dental ulcer prevention or treatment | |
| CN102872060B (en) | Application of Gypensapogenin B to preparing drugs for treating or preventing canker sores | |
| CN103381160A (en) | Applications of Chukrasone B in medicines used for curing or preventing oral ulcer | |
| CN103027918A (en) | Application of Houttuynoid E in preparation of drug for treating or preventing oral ulcer | |
| CN103127086A (en) | Application of Eryngiolide A in medicines curing or preventing dental ulcer | |
| CN103393655A (en) | Application of Sarcaboside B to medicament for treatment and prevention of oral ulcer | |
| CN103505464B (en) | The application of Phyllanthoid A in preparation treatment or preventing canker sore medicine | |
| CN103356549A (en) | Application of Sarcaboside A in medicine for treating or preventing oral ulcer | |
| CN103462998A (en) | Application of Neonectrolide A in preparing medicament for treating or preventing dental ulcer | |
| CN1231242C (en) | Medication composition for children 's virus pneumonia and its preparation method | |
| CN103638005B (en) | The application of Hippolachnin A in treatment or preventing canker sore medicine | |
| CN105232531A (en) | Application of Penifulvin A in preparing drugs for treating or preventing dental ulcers | |
| CN106265638A (en) | Linderolide H application in preparation treatment or preventing canker sore medicine | |
| CN109692255A (en) | A kind of Chinese medicine composition and its preparation method and application for treating acute tracheobronchitis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C04 | Withdrawal of patent application after publication (patent law 2001) | ||
| WW01 | Invention patent application withdrawn after publication |
Application publication date: 20130605 |